FI113865B - Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa - Google Patents

Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa

Info

Publication number
FI113865B
FI113865B FI961696A FI961696A FI113865B FI 113865 B FI113865 B FI 113865B FI 961696 A FI961696 A FI 961696A FI 961696 A FI961696 A FI 961696A FI 113865 B FI113865 B FI 113865B
Authority
FI
Finland
Prior art keywords
phenyl
quinoline
deriv
tetrahydropyridazino
aryl
Prior art date
Application number
FI961696A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI961696A0 (fi
FI961696A (fi
Inventor
Thomas Michael Bare
Richard Bruce Sparks
James Roy Empfield
Timothy Wayne Davenport
Jeffrey Alan Mckinney
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of FI961696A0 publication Critical patent/FI961696A0/fi
Publication of FI961696A publication Critical patent/FI961696A/fi
Priority to FI970907A priority Critical patent/FI114916B/fi
Application granted granted Critical
Publication of FI113865B publication Critical patent/FI113865B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FI961696A 1993-10-22 1996-04-18 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa FI113865B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI970907A FI114916B (fi) 1993-10-22 1997-03-03 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds
PCT/GB1994/002295 WO1995011244A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Publications (3)

Publication Number Publication Date
FI961696A0 FI961696A0 (fi) 1996-04-18
FI961696A FI961696A (fi) 1996-04-18
FI113865B true FI113865B (fi) 2004-06-30

Family

ID=26303731

Family Applications (2)

Application Number Title Priority Date Filing Date
FI961696A FI113865B (fi) 1993-10-22 1996-04-18 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa
FI970907A FI114916B (fi) 1993-10-22 1997-03-03 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI970907A FI114916B (fi) 1993-10-22 1997-03-03 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa

Country Status (30)

Country Link
US (3) US5744471A (no)
EP (2) EP0724583B1 (no)
JP (1) JP3583132B2 (no)
KR (1) KR100261209B1 (no)
CN (1) CN1053189C (no)
AT (2) ATE295846T1 (no)
AU (2) AU688393B2 (no)
CA (1) CA2171332A1 (no)
CZ (1) CZ292311B6 (no)
DE (2) DE69426422T2 (no)
DK (2) DK1004582T3 (no)
ES (2) ES2154686T3 (no)
FI (2) FI113865B (no)
GB (1) GB9420590D0 (no)
GR (1) GR3035080T3 (no)
HK (1) HK1013997A1 (no)
HU (1) HUT74161A (no)
IL (1) IL111266A (no)
MY (2) MY132875A (no)
NO (1) NO306995B1 (no)
NZ (2) NZ329303A (no)
PL (1) PL180679B1 (no)
PT (2) PT1004582E (no)
RU (1) RU2168511C2 (no)
SG (2) SG59971A1 (no)
SI (2) SI0724583T1 (no)
SK (1) SK282491B6 (no)
TW (1) TW406082B (no)
UA (1) UA60291C2 (no)
WO (1) WO1995011244A1 (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9507318D0 (en) 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
SI1244662T1 (no) * 1999-12-23 2005-08-31 Astrazeneca Ab
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
MXPA02006154A (es) * 1999-12-23 2002-12-05 Astrazeneca Ab Compuesto y metodo para el tratamiento del dolor.
EP1244663B1 (en) * 1999-12-23 2004-08-25 AstraZeneca AB Compounds and methods for the treatment of pain
NZ519390A (en) * 1999-12-23 2003-07-25 Astrazeneca Ab 7-Chloro-4-hydroxy-2-(2-chloro-4-methylphenyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione useful for treating pain
AU2420201A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Compounds and methods for the treatment of pain
ATE321045T1 (de) * 1999-12-23 2006-04-15 Methoden und zusammensetzungen zur behandlung von schmerzen
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
JP2003519147A (ja) * 1999-12-23 2003-06-17 アストラゼネカ・アクチエボラーグ 痛みの処置のための化合物および方法
JP2003518500A (ja) * 1999-12-23 2003-06-10 アストラゼネカ・アクチエボラーグ 痛みの処置のための方法および組成物
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
US6946463B2 (en) 2000-09-29 2005-09-20 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain
JP2004509962A (ja) 2000-09-29 2004-04-02 アストラゼネカ・アクチエボラーグ １，２，５，１０−テトラヒドロピリダジノ［４，５−ｂ］キノリン−１，１０−ジオン及び疼痛治療のためのその使用
JP2004509964A (ja) 2000-09-29 2004-04-02 アストラゼネカ・アクチエボラーグ ７−クロロ−４−ヒドロキシ−２−（２−ピリジルエチル）−１，２，５，１０−テトラヒドロピリダジノ［４，５−ｂ］キノリン−１，１０−ジオン及び疼痛治療のためのその使用
JP2004509963A (ja) * 2000-09-29 2004-04-02 アストラゼネカ・アクチエボラーグ １，２，５，１０−テトラヒドロピリダジノ［４，５−ｂ］キノリン−１，１０−ジオン及び疼痛治療のためのその使用
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
BR0209719A (pt) * 2001-05-31 2004-07-27 Sanofi Synthelabo Derivados de aminoquinolina e aminopiridina e seu uso como ligandos de adenosina a3
WO2005012309A1 (en) 2003-08-04 2005-02-10 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
PL1773816T3 (pl) 2004-06-24 2015-06-30 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą ATP
JP2009521468A (ja) * 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｂｃ輸送体の調節因子としてのキノリン−４−オン誘導体
HUE049976T2 (hu) * 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
KR101852173B1 (ko) 2009-03-20 2018-04-27 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
BR112014021090B1 (pt) 2012-02-27 2023-01-24 Vertex Pharmaceuticals Incorporated Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
IL111266A (en) * 1993-10-22 2002-03-10 Zeneca Ltd 2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
HUT74161A (en) 1996-11-28
CN1138332A (zh) 1996-12-18
GB9420590D0 (en) 1994-11-30
FI970907A (fi) 1997-03-03
PT724583E (pt) 2001-03-30
EP0724583B1 (en) 2000-12-13
JP3583132B2 (ja) 2004-10-27
CA2171332A1 (en) 1995-04-27
US6232313B1 (en) 2001-05-15
AU688393B2 (en) 1998-03-12
PL180679B1 (en) 2001-03-30
NO961584D0 (no) 1996-04-19
US6103721A (en) 2000-08-15
DE69434380D1 (de) 2005-06-23
IL111266A0 (en) 1994-12-29
FI961696A0 (fi) 1996-04-18
IL111266A (en) 2002-03-10
DE69426422D1 (de) 2001-01-18
SG92630A1 (en) 2002-11-19
JPH09504519A (ja) 1997-05-06
CN1053189C (zh) 2000-06-07
ES2241513T3 (es) 2005-11-01
NO961584L (no) 1996-04-19
SI0724583T1 (en) 2001-04-30
CZ113896A3 (en) 1996-09-11
HU9600889D0 (en) 1996-06-28
PL314041A1 (en) 1996-08-05
SI1004582T1 (no) 2005-08-31
DK0724583T3 (da) 2001-03-05
NO306995B1 (no) 2000-01-24
SK282491B6 (sk) 2002-02-05
EP0724583A1 (en) 1996-08-07
EP1004582A3 (en) 2000-08-30
ES2154686T3 (es) 2001-04-16
AU6899998A (en) 1998-07-30
KR100261209B1 (ko) 2000-09-01
FI961696A (fi) 1996-04-18
SG59971A1 (en) 1999-02-22
AU721139B2 (en) 2000-06-22
US5744471A (en) 1998-04-28
WO1995011244A1 (en) 1995-04-27
DK1004582T3 (da) 2005-08-15
ATE295846T1 (de) 2005-06-15
MY132875A (en) 2007-10-31
CZ292311B6 (cs) 2003-09-17
GR3035080T3 (en) 2001-03-30
RU2168511C2 (ru) 2001-06-10
DE69426422T2 (de) 2001-05-10
UA60291C2 (uk) 2003-10-15
EP1004582A2 (en) 2000-05-31
AU7944094A (en) 1995-05-08
DE69434380T2 (de) 2006-05-04
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
ATE198072T1 (de) 2000-12-15
EP1004582B1 (en) 2005-05-18
NZ329303A (en) 2000-01-28
FI970907A0 (fi) 1997-03-03
NZ275472A (en) 1998-03-25
SK50496A3 (en) 1997-03-05
MY124316A (en) 2006-06-30
FI114916B (fi) 2005-01-31
HK1013997A1 (en) 1999-09-17

Similar Documents

Publication Publication Date Title
FI113865B (fi) Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa
BR9707495A (pt) Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
EA199901014A1 (ru) C-4"-замещенные макролидные производные
KR920701165A (ko) 골수세포형성 촉진에 유용한 헤테로아릴-3-옥소-프로판니트릴 유도체
DE60216610D1 (de) Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck
SE9904177D0 (sv) Novel compounds
ATE404558T1 (de) Antimikrobielle 4-oxochinolizinverbindungen, die als teilstruktur ein 2-pyridonskelett aufweisen
GB9124002D0 (en) Benzimidazole anthelmintic agents
FI954340A (fi) Menetelmä uusien terapeuttisesti käytt¦kelpoisten 5-substituoitu tia-sykloalka-ÄdÜ-1,2,4-triatsoloÄ1,5-aÜpyrimidiinijohdannaisten valmistamiseksi